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TRANSFECTION 
Objective: Liposomes may be an appropriate transfection vehicle for trans- 
planted hearts, avoiding the use of viruses in immunosuppressed hosts and 
allowing transfection of nondividing cells. To study whether liposome- 
mediated transfection could be accomplished during transplantation, we 
used a liposome-reporter g ne system in a rabbit model of allograft cardiac 
transplantation. Methods: After aortic crossclamping, Stautfiand donor 
hearts were injected with 10 ml Stanford cardioplegic solution; then a 1.3 to 
2.0 mg/kg dose of chloramphenicol acetyl transferase in 1:1 deoxyribonu- 
cleic acid-liposome complexes was injected proximal to the aortic cross- 
clamp for coronary artery perfusion. The hearts were transplanted into 
New Zealand White rabbit recipients in the heterotopic cervical position 
(n = 11 transplants). Recipients were sacrificed at 24 hours. Myocardial 
specimens (right and left ventricles) and vascular specimens (epicardial 
coronary artery, aortic root, and coronary sinus) from both the trans- 
planted and native hearts were analyzed for chloramphenicol acetyl trans- 
ferase protein by means of the enzymatic liquid scintillation assay (counts 
per minute per milligram of total protein). Results: In the recipient, 
myocardial chloramphenicol acetyl transferase activity was significantly 
greater in treated donor hearts (mean 4.6 x 105 cpm/mg -+ 1.1 x l0 s 
[standard error]) than in native hearts (mean 4.1 × 102 cpm/mg - 72 
[standard error],p < 0.01, Mann-Whitney U test). In treated onor hearts, 
right and left ventricular specimens, as well as apical and basal myocardial 
specimens, were transfected equally. Chloramphenicol acetyl transferase 
activity in vascular specimens also indicated transfection (mean 5.4 x l0 s 
cpm/mg -+ 2.5 × l0 s [standard error]). Chloramphenicol acetyl transferase 
activity in the coronary sinus was comparable with that in the coronary 
arteries, which suggests that liposomes can traverse the coronary capillary 
beds. Conclusions: These findings demonstrate hat ex vivo transfection of 
donor hearts with a liposome-reporter gene system results in significant in 
vivo expression of the transfected gene product after cardiac transplantation. 
Genetic alteration of myocardium and cardiac vasculature has potential 
clinical applications in the prevention of posttransplantation rejection, isch- 
emia-reperfusion injury, and both transplant and nontransplant coronary 
artery disease. (J TnORAC CARDIOVASC SURG 1996;111:416-22) 
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G ene therapy during transplantation has wide- 
spread potential applications in clinical medi- 
cine and vascular biology. Transfection of donor 
hearts before cardiac transplantation might create a 
form of "organ-specific immunosuppression" by 
modifying immune or inflammatory pathways, such 
as cytokine, growth factor, or adhesion molecule 
expression i  the graft. Posttransplantation rejection 
and arteriopathy might be reduced, as suggested by 
studies in which antibody blockade of these pathways 
has been used. 1-5 Requirements for immunosuppres- 
sion might be decreased or obviated. Despite these 
benefits, the risks would be limited only to the donor 
receiving the transfection treatment, with the recipient 
remaining unaffected. 
Transfection of vascular tissues in multiple animal 
models has been variably successful, but most pre- 
vious attempts have used viral vectors. The require- 
ment for viral vectors to introduce desired genes 
into donor organs has limited immediate clinical 
applications in transplantation, inasmuch as the 
risks of retroviruses and adenoviruses in immuno- 
suppressed recipients remain unknown. The advent 
of a noninfectious method, l iposome-mediated 
transfection, would allow gene therapy to be ex- 
tended safely to transplanted organs. Early descrip- 
tions of efficient systemic transfection with reporter 
genes in mice after peripheral venous injection 6
have prompted the investigation of liposome-medi- 
ated transfection i  a rabbit model of cardiac trans- 
plantation. 
Transplantation provides an opportunity to trans- 
fect the donor organ ex vivo. This ex vivo organ is 
isolated from the recipient circulation to localize 
and to concentrate the administered eoxyribonu- 
cleic acid (DNA). The recipient, then, is exposed to 
neither systemic transfection or its attendant pos- 
sible risks. The data regarding transfection during 
transplantation, however, remain scarce. 7 
This project was designed to determine the feasi- 
bility of transfecting donor hearts ex vivo, to assess 
the activity of a transfected gene after transplantation, 
and to examine regional differences in transfection 
within the myocardium. To meet these objectives, we 
investigated transfection of donor hearts in a standard 
rabbit model of cardiac transplantation. Liposome- 
mediated transfection with a reporter gene was se- 
lected as the mechanism of gene transfer. 
Materials and methods 
Heterotopic ardiac transplantation was performed in 
11 treated rabbit transplants with the use of ex vivo 
transfection of the donor heart. In each transplant, he 
untreated native heart served as the control for the 
transfected donor heart in the same recipient. 
Animals. Stautttand rabbits were used as heart donors 
and New Zealand White rabbits as recipients (R & R 
Rabbitry, Stanwood, Wash.). The transplant pairs were 
matched in weight: donor mean 1.4 kg, range 1.1 to 1.7 kg; 
recipient mean 1.5 kg, range 1.3 to 1.6 kg. Humane animal 
care complied with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
Liposomes. DNA-liposome complexes were made 
with cationic and neutral lipid (1:1) liposomes mixed 
with plasmid DNA to form a supercomplex (Megabios 
Corporation, Burlingame, Calif.). The chloramphenicol 
acetyl transferase (CAT) expression vector contains the 
human cytomegalovirus enhancer and promoter, as well 
as a 5' intron from the preproinsulin gene. s The CAT 
gene is followed by the SV40 early region poly A site. 
These liposomes were administered in 5% dextrose in 
water solution as 1.5 mg DNA per milliliter water. 
Animal preparation. Anesthesia was induced with a 
mixture of ketamine (35 mg/kg), xylazine (5 mg/kg), and 
atropine (0.032 mg/kg) given intramuscularly. After 
endotracheal intubation, general anesthesia was main- 
tained with halothane in 100% oxygen by mechanical 
ventilation. Both donor and recipient rabbits were given 
heparin (1000 U and 500 U intravenously, respectively). 
Donor heart excision. The donor venae cavae were 
ligated and transected; the pulmonary artery was 
transected. After the aorta was crossclamped, cold (4 ° C) 
Stanford cardioplegic solution (10 ml) was infused into 
the ascending aorta for coronary perfusion. 
Liposome-mediated transfection. CAT-liposomes, 1.3 
to 2.0 mg/kg DNA diluted in 6 ml of cold (4 ° C) 5% 
dextrose in water, were injected into the isolated donor 
heart proximal to the aortic crossclamp after cardioplegic 
arrest. After ligation of the pulmonary veins, the excised 
donor heart was stored in iced heparinized saline solution 
until its implantation. 
Cardiac transplants. The transfected donor heart was 
transplanted into the recipient by anastomosing the donor 
ascending aorta to the recipient carotid artery and the 
donor pulmonary artery to the recipient jugular vein in an 
end-to-side fashion, a modification of the Carrel tech- 
nique.i, 9 The mean ischemic time for this series was 41 _+ 
6 minutes. The donor heart was resuscitated to spontane- 
ous, continuous beating when blood flow was restored. 
The recipient rabbit was extubated and allowed to re- 
cover. Recipients were sacrificed 24 hours after the trans- 
plant operation with euthanasia solution (2.2 ml/kg intra- 
venously) after anticoagulation (heparin, 500 U/kg, given 
intravenously). 
Specimen preparation. All donor and native hearts 
were excised and sectioned transversely to obtain apical 
and basal transmural myocardial samples from both the 
right and left ventricles of each heart. Specimens of 
approximately 125 mm 3 (5 × 5 × 5 mm) of left anterior 
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Fig. 1. Gene product expression i myocardial specimens. Mean CAT activity, measured by CAT assay, in 
CAT-liposome treated transplanted donor hearts compared with untreated native hearts excised 24 hours 
after transplantation; n = 11. Error bars represent the standard errors of the mean. The error bar for the 
left ventricular apical specimens has been interrupted to maintain scale. 
descending epicardial coronary artery, a 5 mm length of 
aortic root including the coronary ostia, and the entire 
coronary sinus were also removed from the donor hearts. 
Specimens were frozen in liquid nitrogen. 
CAT assay. All cardiac tissue samples were homoge- 
nized to cell extracts and aliquots of the supernatants were 
divided between the two assays described later. The 
supernatants were incubated with 14C-chloramphenicol 
and n-butyryl coenzyme A (Promega kit, Promega Corp., 
Madison, Wis.) for 2 hours at 37 ° C. A liquid scintillation 
CAT assay was performed as described by Gorman, 
Moffatt, and Howard. a° Total protein content was deter- 
mined for each sample with BCA protein assay (Pierce kit, 
Pierce Chemical Company, Rockford, Ill.). Data are ex- 
pressed as ratios of CAT activity, in counts per minute, to 
total protein weight, in milligrams, of the tissue sample 
(cpm/mg) and include the standard error of the mean 
(SE). 
Statistics. Statistical nalysis of the data was performed 
by an independent observer. 
Myocardial specimens. Ranked analysis of the data from 
the myocardial specimens was used. Median CAT activi- 
ties from the myocardial specimens were compared be- 
tween corresponding donor and native heart sections by 
the Mann-Whitney U test. Also, for each heart, the 
median CAT activity of all right ventricular myocardial 
specimens was compared with the median from all left- 
sided specimens by means of Pearson's correlation. The 
mean CAT activities of apical and basal myocardial 
specimens were compared by repeated-measures analysis 
of variance (ANOVA). 
Vascular specimens. For specimens in each vascular 
location (epicardial coronary artery, aortic root, and cor- 
onary sinus), the mean CAT activity in all donor hearts 
was compared with the means of the other two vascular 
sections in donor hearts and with the donor myocardial 
samples by means of ANOVA. 
Results 
Myocardial transfection. CAT activity, assayed 
by liquid scintillation, was compared between the 
myocardial samples for treated donor and control 
native hearts (Fig. 1). For each myocardial section, 
CAT activity was significantly higher in the treated 
donor hearts than in the untreated native hearts, 
indicating transfection (p < 0.01, Mann-Whitney U
test). Furthermore, the magnitude of this difference 
was remarkable: the mean CAT activity in donor 
hearts, 4.6 × 105 cpm/mg _ 1.1 × 105 (SE) was 
1000-fold greater than the mean activity in native 
hearts, 4.1 × 102 cpm/mg _+ 72 (SE). Transfection 
appeared to be well distributed throughout all re- 
gions of the donor heart. For each heart, no signif- 
icant difference was demonstrated between right 
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Fig. 2. Gene product expression i  vascular specimens. Mean CAT activity, measured by CAT assay, in 
CAT-liposome treated transplanted donor hearts excised 24 hours after transplantation; n =11. Error bars 
represent the standard errors of the mean. Note that the scale in this figure is different from that in Fig. 
1. 
versus left ventricle (p > 0.05, Pearson's correla- 
tion). Also, mean myocardial CAT activities were 
not different between apical and basal sections (p > 
0.05, ANOVA). 
Vascular transfection. Fig. 2 illustrates the mean 
CAT activities recorded from the vascular speci- 
mens in treated transplanted onor hearts. The 
magnitude of CAT activity in vascular samples 
(mean 5.4 × 105 cpm/mg _+ 2.5 × 105 [SE]) and 
myocardial samples was not different (p > 0.05, 
ANOVA), demonstrating that equivalent transfec- 
tion occurred in these vascular samples. Mean CAT 
activities in the epicardial coronary artery, aortic 
root, and coronary sinus (p > 0.05, ANOVA) were 
not significantly different, which suggests that the 
liposomes crossed the coronary capillary beds. 
Discussion 
These experiments were designed to answer three 
questions: Is ex vivo transfection of donor hearts 
feasible? Will the transfected gene be expressed in 
the allograft after transplantation? Are there re- 
gional differences in the distribution of the trans- 
fected gene in transplanted donor hearts? 
The results demonstrate effective xpression in 
transplanted donor hearts of genes transfected ex 
vivo. In the current study, the gene product of a 
transfected reporter gene was demonstrated at 24 
hours after cardiac transplantation. Persistence of 
liposome-mediated ransfection has been previously 
studied by other researchers in nontransplant mod- 
els. Working with this CAT gene construct, in a 
slightly different liposome formulation by the same 
supplier (Megabios), Zhu and associates 6 reported 
the presence of transfected DNA for up to 9 weeks 
after systemic intravenous delivery. With other lipo- 
some systems used in vivo by Nabel and cowork- 
ers, 11-13 introduced DNA has persisted in trans- 
fected arteries for at least 3 weeks. This time limit 
appears independent of the gene or animal model 
used. Although this study demonstrates that gene 
expression is intact after the ischemic insult of the 
operation, it is unclear whether similar long-term 
expression can be expected after transplantation; 
gene expression in the donor heart might also be 
affected by the transplant recipient's immunologic 
response to the donor organ and by cell turnover. 
Nonetheless, the magnitude of the reporter product 
expression at 24 hours in this study is an auspicious 
early result. Recent work in this laboratory with this 
rabbit cardiac transplant model has demonstrated 
graft infiltration by neutrophils, as well as some 
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T-lymphocytes, at 24 hours; expression of trans- 
fected genes even at 24 hours, then, might be useful 
in ameliorating ischemia-reperfusion phenomenon 
or early graft rejection) In transplantation, nonper- 
manent or transient gene expression of 3 to 9 weeks' 
duration may be sufficient o modify the recipient 
immune response on initial exposure to donor anti- 
gens until natural accommodation to the graft de- 
velops. 
In this study, no regional differences were found 
in donor heart transfection. This global nature of 
transfection is probably the result of .nonspecific 
binding of the cationic liposome-DNA complexes to 
any cell membrane to which they are exposed. 14' i5 
Also, CAT activities indicated similar transfection i  
the epicardial coronary arteries and the coronary 
sinus, suggesting that liposomes can cross the coro- 
nary capillary bed. Inasmuch as high endothelial 
cell-like venules are the site of lymphocyt e emigra- 
tion into the myocardium, 1 this feature of liposome- 
mediated transfection may prove important in gene 
therapy directed at the treatment or prevention of 
rejection. 
Since their introduction by Feigner and associ- 
ates 14 in 1987, liposomes have been demonstrated to 
provide both a safe 6' 16, 17 and efficient 18 method of 
gene transfection. Liposome-mediated transfection 
does not require cell division, an advantage for cells, 
such as cardiac myocytes and coronary endothelial 
cells, with slow turnover. Because of the rapid 
uptake across cell membranes, highly loc.alized 
transfection is possible, 19'2° thus decreasing or 
avoiding systemic genetic modification. 
Other laboratories, using a different lipid formu- 
lation of CAT-liposomes by the same manufacturer 
(Megabios), have reported efficient transfection of 
viscera after intravenous administration, 6 spleen 
and abdominal lymph nodes after intraperit0neal 
injection, 18 and lung after endotracheal erosoliza- 
tion in mice. 19 Liposome-mediated ransfection has 
also been used with success to transfer eporte r 
genes into isolated peripheral and thoracic arteries 
in vivo TM 2o-23 and into vascular smooth muscle cells 
in cell culture. 22' 24 Recently, biologically functional 
genes have been transfected into rabbit aortic endo- 
thelial cells in organ culture 25 and into porcine 
peripheral arteries in situ. 12' 13 
Viral vectors, usually retrovirus or adenovirus, are 
the more frequent current alternatives to liPosomes 
for vascular transfection. Retrovirus has been used 
to introduce reporter genes into rat myocardium by 
direct ventricular injection. 26 Viral transduction of
peripheral arteries has been accomplished with re- 
porter genes, both by direct instillation of retrovirus 
or adenovirus into isolated segments and by seeding 
of cultured cells transduced with retrovirus. 20' 27-30 
Viral transduction, though, is plagued by various 
technical difficulties, and the biologic consequences 
of a viral vector in an immunosuppressed host are 
unknown. Additionally, antibodies to adenovirus 
may develop over time, which would limit further 
therapy. 
This study shows that liposome-mediated trans- 
fection might provide a practical alternative to viral 
vectors as an efficient ransfection agent for donor 
hearts. The ex vivo gene delivery technique could 
also serve as a model for transfection of hearts 
during routine nontransplant cardiac operations, 
because the heart is similarly isolated from the 
systemic irculation during instillation of cardiople- 
gic solution with the aortic crossclamp in place. 
Either antegrade coronary arterial or retrograde 
coronary sinus perfusion might be used. Further 
work will be needed to determine the duration of 
transfected gene expression in both transplanted 
and nontransplanted hearts. Histologic identifica- 
tion of the specifc cell types transfected will deter- 
mine which gene targets are chosen for modifica- 
tion, for example, diffusable cytokines or growth 
factors versus cell-specific gene products. 
Conclusions 
This project demonstrates that ex vivo liposome- 
mediated transfection of donor hearts results in in 
vivo expression of the transfected gene in the recip- 
ient for at least 24 hours after transplantation. After 
aortic root injection, liposomes appear to be distrib- 
uted equally to all myocardial segments of the heart 
and provide transfection i both coronary arterial 
and venous beds. In future applications, liposome- 
mediated transfection might allow localized genetic 
alteration of donor organs for amelioration ofpost- 
transplantation rejection, ischemia-reperfusion n- 
jury, and both transplant and nontransplant coro- 
nary arteriopathy. 
Statistical nalysis was performed by Robert Bergelin, 
MS. We thank Christine L. Rothnie for animal care. Molly 
McClarrinon for manufacturing the liposome-DNA com- 
plexes, and Chris Lapuz for performing the CAT assays. 
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Discussion 
Dr. Adnan Cobanoglu (Portland, Ore.). In the past 
decade major advances in molecular biology, gene trans- 
fer, and gene targeting techniques have resulted in dra- 
matic expansion of the field of human gene therapy. This 
effort by the University Of Washington group is one of the 
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few efforts to extend these advances in molecular biology 
to the transplantation arena and into heart transplanta- 
tion. The application of gene transfer techniques to organ 
transplantation would offer the possibility of modification 
of antigen expression in the transplanted tissues. The 
major obstacle to therapeutic management of human 
disease has been the site-specific expression of genes in 
vivo. The objective Of gene therapy is the efficient delivery 
of the desired genetic material to target cells, resulting in 
stable and localized production of biologically effective 
recombinant protein. Dr. Dalesandro has shown us that 
cationic liposome-mediated transfection is an efficient 
method of gene transfection and that when transfected ex 
vivo the gene is expressed in the transplanted heart 24 
hours after transplantation. I  their study the distribution 
of the DNA-liposome complexes was homogeneous in the 
myocardium, and there was no regional difference in 
donor heart transfection. A few other studies like this one 
have shown that circulating DNA-liposome complexes 
appear to readily extravasate across vascular endothelial 
barriers in all tissues. 
Because of access to donor organ at the time of 
procurement, his technique is uniquely appealing for 
heart transplant surgeons. The donor organ antigenicity 
can be controlled by controlling human lymphocyte anti- 
gen expression via antisense oligonucle0tide transfer. 
Also, through efforts like this one, genetic modification of 
nonhuman hearts may allow xenotransplantation. 
I have a few questions for the authors, some of which 
were addressed as future areas of investigation. Will the 
expression of the transfected plasmid DNA modify bio- 
logic function of the arteries or myocardium? 
Dr. Dalesandro. Modification of the function of coro- 
nary vasculature and myocardium iscertainly agoal of this 
project. In part, gene selection will be determined by the 
transfection pattern on histologic features, but at this 
point our histologic system is not perfected. If histologic 
studies demonstrate hat a few focal cells are transfected, 
we would target a gene encoding a diffusible protein. On 
the other hand, if histologic studies show widespread 
transfection of the majority of cells, including the endo- 
thelium, then we would try to affect endothelial expression 
of surface molecules. 
Dr. Cobanoglu. The endothelium seems to have higher 
relative expression of the CAT antigen than myocytes. 
What do you think the duration of the gene expression i  
the transfected myocardium will be? 
Dr. Dalesandro. We plan to study that in the future. 
Other work in which this type of liposome was used has 
demonstrated in both vascular and nonvascular tissues 
that the duration of the transfection can be up to 11 
weeks. In published work, the longest ransfection dura- 
tion is 9 weeks. The experiment that we plan for the 
immediate future deals with the duration of the transfec- 
tion in this cardiac transplantation system. We expect o 
see a similar duration, that is, about 3 months, but a 
duration study using liposome-mediated transfection i a 
transplantation model has not been reported previously. 
Dr. Cobanoglu. Were any histologic studies done in 
these experiments? 
Dr. Dalesandro. We have attempted now with two 
separate monoclonal antibodies to demonstrate he site- 
specific localization of the CAT protein, but we have not 
yet evaluated those systems fully. I can discuss only the 
preliminary results. With the use of cell blocks from 
transfected onor hearts with the highest CAT assay 
values, immunocytochemical staining would indicate that 
only a few of the cells within the cell block have been 
transfected. These transfected cells, however, have been 
producing CAT protein vigorously. 
Dr. Cobanoglu. Was there an acute cellular ejection or 
interstitial cellular infiltration? 
Dr. Dalesandro. Yes, there was. At 24 hours the cellular 
reaction represents mostly ischemic damage, with neutro- 
phils seen as the predominant cell type. This rabbit 
cardiac transplantation model produces full rejection, 
with lymphocytic and macrophage infiltrates, within 1 
week. As we complete our duration studies, we will be 
seeing these other cellular infiltrates and we can evaluate 
how that inflammation is interfering or aiding in our 
transfection. Interestingly, one of our most consistent 
observations i that the hearts that grossly provide the 
most evidence of ischemic damage at 24 hours tend to 
have the most evidence of transfection represented by the 
highest levels of CAT activity. 
Dr. Cobanoglu. Quite a few good investigative models 
and experiments have been developed in rabbits and mice. 
What is the next step? 
Dr. Dalesandro. We believe that we have much more 
work to do with our system, so we will continue our work 
with the rabbit heart ransplantation model and possibly a
carotid transplantation model, which we have also at- 
tempted. Once we have those systems defined, particularly 
after we know the histologic features of the transfection, 
then we will be able to progress to work in nonhuman 
primates and then to human beings. 
Dr. D. Craig Miller (Stanford, Calif.). ls the word 
transfection still semantically correct inaasmuch as this is 
not a virally mediated taxicab? 
Dr. Dalesandro. Yes, it is. The word transduction is 
specific to biologically active systems and particularly to 
viruses; however, when a nonbiologically active system is 
used, such as liposomes or a calcium phosphate system, 
then the word transfection is appropriate. 
Dr. David A. Fullerton (Denver, Colo.). Have you 
compared the efficiency of your transfection with that of a 
viral carrier? 
Dr. Dalesandro. No, we have not, and again the limita- 
tion has been histology. Currently we are looking for 
systems that have better histologic markers as end-prod- 
uct proteins. As soon as we develop such a system, we will 
be able to investigate the transfection efficiency. 
